
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated strong growth, with sales increasing by 29% to $803 million for the year 2024, and management projecting an optimistic sales range of $940 million to $955 million for the upcoming periods. The company is expected to benefit from improved market share of its aura6000 product, with a potential increase from 2.4% in 2027 to 4.2% in 2029 under a Bear Case scenario, and even more favorable projections suggesting growth to 14.9% in the Bull Case. With around half of its revenue originating from the US market and a well-defined focus on its medical-device portfolio, LivaNova's strategic positioning supports a promising financial outlook.
Bears say
LivaNova's financial outlook appears unfavorable, primarily due to anticipated revenue growth decelerating to low single digits, which is attributed to ongoing challenges in its Neuromodulation and Cardiovascular segments. Additionally, the firm faces operational margin contraction and below-consensus earnings, further exacerbating its financial position. Risks associated with obtaining FDA approval for new products, coupled with slower-than-expected growth in both Neuromodulation and Cardiopulmonary sectors, heighten concerns regarding the company's profitability and market performance moving forward.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares